Table 17.1Fish oil capsules vs. placebo for stable angina (Follow-up at end of treatment period)

Quality assessmentSummary of findings
No of patientsEffectQuality
No of studiesDesignLimitationsInconsistencyIndirectnessImprecisionOther considerationsFish oil capsulesPlacebo (Follow-up at end of treatment period)Relative (95% CI)Absolute
Anginal episodes per week (better indicated by lower values) (Follow-up at the end of 12 weeks treatment period)
Salachas 1994213randomised trialsserious (a)no serious inconsistencyno serious indirectnessserious imprecision (c)none2019-MD 3 lower (54.01 lower to 48.01 higher)⊕⊕○ ○

LOW
GTN consumption per week (better indicated by lower values) (Follow-up at the end of 12 weeks treatment period)
Salachas 1994213randomised trialsserious (a)no serious inconsistencyno serious indirectnessserious imprecision (c)none2019-MD 1.99 lower (10.69 lower to 6.71 higher)⊕ ⊕ ○ ○

LOW
Exercise test duration (min) (better indicated by higher values) (Follow-up at the end of 12 weeks treatment period)
Salachas 1994213randomised trialsserious (a)no serious inconsistencyno serious indirectnessserious imprecision (c)none2019-MD 0.99 higher (2.01 lower to 3.99 higher)⊕ ⊕ ○ ○

LOW
Number of anginal attacks per 30 days (better indicated by lower values) (Follow-up at the end of 12 weeks treatment period)
Aucamp 1993214randomised trialsvery serious (b)no serious inconsistencyno serious indirectnessserious imprecision (c)none1211-MD 9.2 lower (29.15 lower to 10.75 higher)⊕ ○ ○ ○

VERY LOW
Duration of angina attacks per minute (better indicated by lower values) (Follow-up at the end of 12 weeks treatment period)
Aucamp 1993214randomised trialsvery serious (b)no serious inconsistencyno serious indirectnessno serious imprecisionnone1211-MD 0.4 lower (0.95 lower to 0.15 higher)⊕ ⊕ ○ ○

LOW
Intensity of pain per attack per patient (on a 10 cm visual analogue scale) (better indicated by lower values) (Follow-up at the end of 12 weeks treatment period)
Aucamp 1993214randomised trialsvery serious (b)no serious inconsistencyno serious indirectnessno serious imprecisionnone1211-MD 1 lower (2.12 lower to 0.12 higher)⊕ ⊕ ○ ○

LOW
No. of sublingual isosorbide dinitrate tablets taken per 30 days (better indicated by lower values) (Follow-up at the end of 12 weeks treatment period)
Aucamp 1993214randomised trialsvery serious (b)no serious inconsistencyno serious indirectnessserious imprecision (c)none1211-MD 0 higher (16.14 lower to 16.14 higher)⊕ ○ ○ ○

VERY LOW
a

Salachas 1994[207]: Randomised. Double blind. Allocation concealment not reported. Numbers lost to follow-up not reported. No ITT reported. Baseline comparison between groups not made.

b

Aucamp 1993[208]: Placebo controlled cross-over trial. Single blind. 23 patients completed the trial: 11 patients taking placebo in phase 1(group A) and 12 patients taking the active fish oil in phase 1 (group B). Very little baseline characteristics reported. No ITT reported. No method of randomisation and allocation concealment reported. Very poorly reported trial.

c

95% CI includes no effect and the upper and lower CI crosses the MID

From: 17, Lifestyle Adjustments

Cover of Stable Angina
Stable Angina: Methods, Evidence & Guidance [Internet].
NICE Clinical Guidelines, No. 126.
National Clinical Guidelines Centre (UK).
Copyright © 2011, National Clinical Guidelines Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of the National Clinical Guidelines Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.